Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History | Funding Information
International Journal of Diabetes & Clinical Diagnosis Volume 2 (2015), Article ID 2:IJDCD-110, 6 pages
http://dx.doi.org/10.15344/2394-1499/2015/110
Research Article
DPP4 Inhibitor Decreases Urinary Albumin Excretion in Association with the Improvement of Glomerular Endothelial Injury in Patients with Type 2 Diabetes

Takayuki Fujita1*,Hidetsuna Watanabe2, Yusuke Murata1, Seiichiro Hemmi1, Minako Yabuki1, Yoshinobu Fuke1, Atsushi Satomura3, Masayoshi Soma4

1Department of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, Tokyo, Japan
2Department of Internal Medicine, SakuboukaiTokiwadaigeka Hospital, Tokyo, Japan
3Department of Laboratory Medicine, Nihon University School of Medicine, Tokyo, Japan
4Department of General Medicine, Nihon University School of Medicine, Tokyo, Japan
Dr. Takayuki Fujita, Department of Nephrology, Hypertension and Endocrinology, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashiku, Tokyo, 173-8610, Japan,Tel: 81 3 3972 8111; Fax: 81 3 3972 8311; E-mail: tfujita@med.nihon-u.ac.jp
26 December 2014; 17 February 2015; 19 February 2015
Fujita T, Watanabe H, Murata Y, Hemmi S, Yabuki M, et al. (2015) DPP4 Inhibitor Decreases Urinary Albumin Excretion in Association with the Improvement of Glomerular Endothelial Injury in Patients with Type 2 Diabetes. Int J Diabetes Clin Diagn 2: 110. doi: http://dx.doi.org/10.15344/2394-1499/2015/110
This work was supported by the constitutional subsidy from Nihon University School of Medecine, Nihon University Itabashi Hospital, and Nihon University Medical Alumni Association.
© 2015 Fujita et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Dinneen SF, Gerstein HC (1997) The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157: 1413-1418. View
  2. Parving HH, Chaturvedi N, Viberti G, Mogensen CE (2002) Does microalbuminuria predict diabetic nephropathy? Diabetes Care 25: 406- 407. View
  3. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, et al. (2004) Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction— the Hoorn Study. Kidney Int 92: S42–S44. View
  4. Satchell SC, Tooke JE (2008) What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 51: 714- 725. View
  5. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, et al. (1998) Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 432: 73-76. View
  6. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, et al. (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10: 858-864. View
  7. Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, et al. (2006) Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler ThrombVasc Bio l26: 2140–2146. View
  8. Maruyama I, Bell CE, Majerus PW (1985) Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 101: 363-371. View
  9. Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, et al. (1990) Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes 39: 983-988. View
  10. Kanauchi M, Nishioka H, Hashimoto T (2002) Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 91: 327-329. View
  11. Mori H, Okada Y, Arao T, Tanaka Y (2014) Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. J Diabetes Investig 5: 313-319. View
  12. Saxena A, Fish JE, White MD, Yu S, Smyth JW, et al. (2008) Stromal cell-derived factor-1alpha is cardioprotective after myocardial infarction. Circulation 117: 2224-2231. View
  13. Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95: 343-353. View
  14. Fadini GP, Maruyama S, Ozaki T, Taguchi A, Meigs J, et al. (2010) Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One 5: e11488. View
  15. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, et al. (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353: 999-1007. View
  16. Hansson GK (2009) Atherosclerosis--an immune disease: The Anitschkov Lecture 2007. Atherosclerosis 202: 2-10. View
  17. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, et al. (2010) The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33: 1607-1609. View
  18. Dobrian AD, Ma Q, Lindsay JW, Leone KA, Ma K, et al. (2011) Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 300: E410-421. View
  19. Lazzara MJ, Deen WM (2007) Model of albumin reabsorption in the proximal tubule. Am J Physiol Renal Physiol 292: F430-439. View
  20. Deen WM, Lazzara MJ, Myers BD (2001) Structural determinants of glomerular permeability. Am J Physiol Renal Physiol 281: F579-596. View
  21. Ballermann BJ (2007) Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol 106: p19- 25. View
  22. Henry CB, Duling BR (2000) TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. Am J Physiol Heart Circ Physiol 279: H2815-2823. View
  23. Nieuwdorp M, Mooij HL, Kroon J, Atasever B, Spaan JA, et al. (2006) Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes 55: 1127-1132. View
  24. Vink H, Duling BR (1996) Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 79: 581-589. View
  25. deVriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH (2001) Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am SocNephrol 12: 993–1000. View
  26. Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EN, et al. (2002) Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Blood 100: 1334–1339. View
  27. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 46: 1402-1407. View
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.